Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3329-3335

  Nio, Yoshinori ^a   Iguchi, Chikage ^a   Itakura, Masayuki ^b   Nishi, Takeshi ^b   Hashimoto, Koji ^c   Takeda, Hiroshi ^c   Takamura, Michio ^c   Omori, Hiroshi ^d   Sato, Yoshitoshi ^d   Koike, Makoto ^d   Endo, Shin Ichiro ^e  

^a Nio Breast Surgery Clinic   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d MATSUE RED CROSS HOSPITAL   (Japan)

^e Toyooka Hospital   (Japan)

Author keywords

Malignant portal vein stenosis; Metallic stent; Pancreatic cancer

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; BIASPIRIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GEMCITABINE; HEPARIN; UFT; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASCITES; BLEEDING TENDENCY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; EXPANDABLE METALLIC STENT; FEMALE; HUMAN; HYPERGLYCEMIA; LAPAROTOMY; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; PANCREAS CANCER; PANCYTOPENIA; PORTAL HYPERTENSION; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; RECURRENT CANCER; STENT; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; STENTS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 68549130592     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Nitecki SS, Sarr MG, Colby TV and van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221: 59-66, 1995.
2. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W and Verslype C: Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16: 265-274, 2004.
3. Tsukamoto T, Hirohashi K, Kubo S, Tanaka H, Hamba H, Shuto T, Higaki I, Takemura S and Kinoshita H: Percutaneous transhepatic metallic stent placement for malignant portal vein stenosis. Hepatogastroenterol 50: 453-455, 2003. (Pubitemid 36390542)
4. NCI-CTC version 2.0. Common toxicity criteria, Notice of modifications (http://ctep.info.nih.gov/).
5. Okusaka T and Kosuge T: Systemic chemotherapy for pancreatic cancer. Pancreas 28: 301-304, 2004.
6. Pasetto LM, Jirillo A, Stefani M and Monfardini S: Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol 49: 135-151, 2004. (Pubitemid 38175440)
7. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Don FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
8. Heinemann V: Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 29(1 Suppl 3): 25-35, 2002. (Pubitemid 34230196)
9. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S and Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592, 1999. (Pubitemid 29075246)
10. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Hanis JE and Benson IIIAB: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncol 58: 215-218, 2000.
11. Cascinu S, Frontini L, Labianca R, Catalano V, Barni S, Graiff C, Picone G, Farinati E, Zonato S, Pessi MA, Curti C and Catalano G: A combination of a fixed dose rate infusion of gemcitabine associated with a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 11: 1309-1311, 2000. (Pubitemid 30832255)
12. Kurtz JE, Kohser F, Negrier S, Trillet-Lenoir V, Walter S, Limacher JM, Untereiner M, Kayitalire L, Jaeck D and Dufour P: Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterol 47: 1450-1453, 2000.
13. Oliani C, Padovani M, Manno P, Barana D, Falconi M, Bassi C, Cavallini G, Pederzoli P and Cetto GL: Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res 24: 2107-2112, 2004. (Pubitemid 38954642)
14. Kanat O, Evrensel T, Kurt E, Demiray M, Gonullu G, Arslan M and Manavoglu O: Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori 90: 192-195, 2004. (Pubitemid 38745607)
15. Novarino A, Chiappino I, Bertelli GF, Heouaine A, Ritorto G, Addeo A, Bellone G, Merlano M and Bertetto O: Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 15: 474-477, 2004. (Pubitemid 38444552)
16. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 20: 3270-3275, 2002.
17. Nio Y, Hashinoto K, Yano S, Itakura M, Koike M, Yamaguchi K, Endo S, Tsuji M, Higami T and Maruyama R: Phase II study on low-dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recunent and advanced pancreatic cancer. Oncol Rep 14: 401-408, 2005.
18. Ohta K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 323-328, 1988. (Pubitemid 18244819)
19. Sulkes A, Benner S and Canetta R: Uracil-tegafur: An oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16: 3461-3475, 1998.
20. Van Cutsem E and Peeters M: Oral fluoropyrimidines in colorectal cancer. Semin Oncol 27(Suppl 10): 91-95, 2000.
21. Ueno H, Okada S, Okusaka T, Ikeda M and Kuriyama H: Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncol 62: 223-227, 2002. (Pubitemid 34639055)
22. Feliu J, Lopez Alvarez MP, Jaraiz MA, Constenla M, Vicent JM, Belón J, López Gómez L, de Castro J, Dorta J and González Baron M: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. Cancer 89: 1706-1712, 2000. (Pubitemid 30794163)
23. Feliu J, Mel R, Borrega P, López Gómez L, Escudero P, Dorta J, Castro J, Vázquez-Estévez SE, Bolaños M, Espinosa E and González Barón M; Oncopaz Cooperative Group, Spain: Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 13: 1756-1762, 2002.
24. Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK and Park K: Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 66: 32-37, 2004. (Pubitemid 38410677)
25. Nio Y: Chemotherapy of pancreatic cancer - Adjuvant chemotherapy. Consensus of Cancer Therapy 2: 28-31, 2003 (in Japanese).
26. Gregory RK, Johnston SR, Smith IE and Miles D: UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. Oncology (Huntingt) 14(10 Suppl 9): 47-49, 2000.
27. Ogawa Y, Ishikawa T, Chung SH, Ikeda K, Takashima T, Onoda N, Nakata B, Nishiguchi Y and Hirakawa K: Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 23: 3453-3457, 2003. (Pubitemid 36975448)
28. Haga S, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Fukushima M and Kajiwara T: Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice. Anticancer Res 19(3A): 1791-1796, 1999. (Pubitemid 29392739)
29. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H and Tanaka Y: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83: 127-134, 1999. (Pubitemid 29409488)
30. Iguchi C, Nio Y, Sato Y, Watanabe H, Ohishi T, Abe M, Yano S, Sumi S and Tamura K: A case of recurrent ampullary carcinoma of the papilla of Vater in which a complete response was induced by combination therapy using radiotherapy and oral chemotherapy employing UFT and cyclophosphamide. Jpn J Cancer Chemother 26: 1641-1645, 1999 (in Japanese).
31. Minari Y, Nio Y, Endo S, Yano S, Itakura M, Yamasawa K, Tamura K: A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy. Jpn J Cancer Chemother 27: 121-125, 2000 (in Japanese).